Cold-attenuated live influenza vaccines, a risk-benefit assessment
Identifieur interne : 001885 ( Main/Exploration ); précédent : 001884; suivant : 001886Cold-attenuated live influenza vaccines, a risk-benefit assessment
Auteurs : Michael Pfleiderer [Allemagne] ; Johannes Löwer [Allemagne] ; Reinhard Kurth [Allemagne]Source :
- Vaccine [ 0264-410X ] ; 2002.
English descriptors
- KwdEn :
- Teeft :
- Adverse reactions, Allergic, Allergic reactions, Allergic subjects, Allergy, Antibody titer, Antigenic, Antigenic shift, Attenuated, Attenuated vaccines, Belshe, Best knowledge, Caiv, Caiv vaccine, Caiv vaccines, Caiv virus, Complementary antibody, Drift variants, Elsevier science, Embryonated eggs, Herd immunity, High attack rates, Human beings, Human population, Human virus, Hypersensitivity reactions, Immune, Immune response, Immune responses, Immunization, Immunogenicity, Immunogenicity data, Internal genes, Intranasal virus vaccine, Normal mucosal barrier, Otitis media, Pandemic, Pandemic disease, Pandemic spread, Pandemic virus, Pandemic viruses, Past years, Phenotypic alterations, Placebo group, Possible risks, Rapid spread, Reassortant, Reassortment, Reassortment event, Respiratory symptoms, Safe administration, Safety data, Same time, Simultaneous administration, Single dose, Skin testing, Surface antigens, Time span, Trivalent, Trivalent caiv, Vaccine, Vaccine recipients, Vaccine strain, Viral, Viral contaminants, Virulent virus, Virus, Virus infection, Virus master seeds, Virus vaccine, Virus vaccines, Wild type, Wild virus, Young children, Zoonotic virus.
Abstract
Abstract: The principle of live attenuated influenza vaccines has been known for many decades. However, the pharmaceutical and clinical development according to current regulations, of modern live influenza vaccines based on cold adapted influenza viruses (CAIV) started only recently and these vaccines will most probably become an alternative within the next couple of years to licensed inactivated influenza vaccines that have been used routinely since the early 1940s. In contrast to contemporary trivalent inactivated influenza vaccines, which are administered intramuscularly, trivalent CAIV-based vaccines will be administered intranasally as a spray. Quality, safety and efficacy aspects related to CAIV vaccines as well as possible risks linked to the widespread use of these vaccines will be discussed in the following overview and compared to established influenza vaccines. Moreover, issues of practicality of CAIV vaccines focusing on the necessity of an annual update of influenza vaccines are addressed.
Url:
DOI: 10.1016/S0264-410X(01)00386-3
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000F32
- to stream Istex, to step Curation: 000F32
- to stream Istex, to step Checkpoint: 000712
- to stream Main, to step Merge: 001925
- to stream Main, to step Curation: 001885
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cold-attenuated live influenza vaccines, a risk-benefit assessment</title><author><name sortKey="Pfleiderer, Michael" sort="Pfleiderer, Michael" uniqKey="Pfleiderer M" first="Michael" last="Pfleiderer">Michael Pfleiderer</name></author><author><name sortKey="Lower, Johannes" sort="Lower, Johannes" uniqKey="Lower J" first="Johannes" last="Löwer">Johannes Löwer</name></author><author><name sortKey="Kurth, Reinhard" sort="Kurth, Reinhard" uniqKey="Kurth R" first="Reinhard" last="Kurth">Reinhard Kurth</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2AF4503993D26C3C4CB4F9CD0A25172199585176</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1016/S0264-410X(01)00386-3</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-K865XNTD-C/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000F32</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000F32</idno><idno type="wicri:Area/Istex/Curation">000F32</idno><idno type="wicri:Area/Istex/Checkpoint">000712</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000712</idno><idno type="wicri:doubleKey">0264-410X:2001:Pfleiderer M:cold:attenuated:live</idno><idno type="wicri:Area/Main/Merge">001925</idno><idno type="wicri:Area/Main/Curation">001885</idno><idno type="wicri:Area/Main/Exploration">001885</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Cold-attenuated live influenza vaccines, a risk-benefit assessment</title><author><name sortKey="Pfleiderer, Michael" sort="Pfleiderer, Michael" uniqKey="Pfleiderer M" first="Michael" last="Pfleiderer">Michael Pfleiderer</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Paul-Ehrlich-Institut, Paul-Ehrlich-Strasse 51-59, D-63225 Langen</wicri:regionArea><wicri:noRegion>63225 Langen</wicri:noRegion><wicri:noRegion>D-63225 Langen</wicri:noRegion></affiliation><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Allemagne</country></affiliation></author><author><name sortKey="Lower, Johannes" sort="Lower, Johannes" uniqKey="Lower J" first="Johannes" last="Löwer">Johannes Löwer</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Paul-Ehrlich-Institut, Paul-Ehrlich-Strasse 51-59, D-63225 Langen</wicri:regionArea><wicri:noRegion>63225 Langen</wicri:noRegion><wicri:noRegion>D-63225 Langen</wicri:noRegion></affiliation></author><author><name sortKey="Kurth, Reinhard" sort="Kurth, Reinhard" uniqKey="Kurth R" first="Reinhard" last="Kurth">Reinhard Kurth</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Robert Koch-Institut, Nordufer 20, D-13353 Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="ISSN">0264-410X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2002">2002</date><biblScope unit="volume">20</biblScope><biblScope unit="issue">5–6</biblScope><biblScope unit="page" from="886">886</biblScope><biblScope unit="page" to="894">894</biblScope></imprint><idno type="ISSN">0264-410X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cold-attenuated influenza virus vaccine</term><term>Possible risk potentials</term><term>Quality, safety, efficacy and practicality</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Adverse reactions</term><term>Allergic</term><term>Allergic reactions</term><term>Allergic subjects</term><term>Allergy</term><term>Antibody titer</term><term>Antigenic</term><term>Antigenic shift</term><term>Attenuated</term><term>Attenuated vaccines</term><term>Belshe</term><term>Best knowledge</term><term>Caiv</term><term>Caiv vaccine</term><term>Caiv vaccines</term><term>Caiv virus</term><term>Complementary antibody</term><term>Drift variants</term><term>Elsevier science</term><term>Embryonated eggs</term><term>Herd immunity</term><term>High attack rates</term><term>Human beings</term><term>Human population</term><term>Human virus</term><term>Hypersensitivity reactions</term><term>Immune</term><term>Immune response</term><term>Immune responses</term><term>Immunization</term><term>Immunogenicity</term><term>Immunogenicity data</term><term>Internal genes</term><term>Intranasal virus vaccine</term><term>Normal mucosal barrier</term><term>Otitis media</term><term>Pandemic</term><term>Pandemic disease</term><term>Pandemic spread</term><term>Pandemic virus</term><term>Pandemic viruses</term><term>Past years</term><term>Phenotypic alterations</term><term>Placebo group</term><term>Possible risks</term><term>Rapid spread</term><term>Reassortant</term><term>Reassortment</term><term>Reassortment event</term><term>Respiratory symptoms</term><term>Safe administration</term><term>Safety data</term><term>Same time</term><term>Simultaneous administration</term><term>Single dose</term><term>Skin testing</term><term>Surface antigens</term><term>Time span</term><term>Trivalent</term><term>Trivalent caiv</term><term>Vaccine</term><term>Vaccine recipients</term><term>Vaccine strain</term><term>Viral</term><term>Viral contaminants</term><term>Virulent virus</term><term>Virus</term><term>Virus infection</term><term>Virus master seeds</term><term>Virus vaccine</term><term>Virus vaccines</term><term>Wild type</term><term>Wild virus</term><term>Young children</term><term>Zoonotic virus</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: The principle of live attenuated influenza vaccines has been known for many decades. However, the pharmaceutical and clinical development according to current regulations, of modern live influenza vaccines based on cold adapted influenza viruses (CAIV) started only recently and these vaccines will most probably become an alternative within the next couple of years to licensed inactivated influenza vaccines that have been used routinely since the early 1940s. In contrast to contemporary trivalent inactivated influenza vaccines, which are administered intramuscularly, trivalent CAIV-based vaccines will be administered intranasally as a spray. Quality, safety and efficacy aspects related to CAIV vaccines as well as possible risks linked to the widespread use of these vaccines will be discussed in the following overview and compared to established influenza vaccines. Moreover, issues of practicality of CAIV vaccines focusing on the necessity of an annual update of influenza vaccines are addressed.</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>Berlin</li></region><settlement><li>Berlin</li></settlement></list><tree><country name="Allemagne"><noRegion><name sortKey="Pfleiderer, Michael" sort="Pfleiderer, Michael" uniqKey="Pfleiderer M" first="Michael" last="Pfleiderer">Michael Pfleiderer</name></noRegion><name sortKey="Kurth, Reinhard" sort="Kurth, Reinhard" uniqKey="Kurth R" first="Reinhard" last="Kurth">Reinhard Kurth</name><name sortKey="Lower, Johannes" sort="Lower, Johannes" uniqKey="Lower J" first="Johannes" last="Löwer">Johannes Löwer</name><name sortKey="Pfleiderer, Michael" sort="Pfleiderer, Michael" uniqKey="Pfleiderer M" first="Michael" last="Pfleiderer">Michael Pfleiderer</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001885 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001885 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:2AF4503993D26C3C4CB4F9CD0A25172199585176
|texte= Cold-attenuated live influenza vaccines, a risk-benefit assessment
}}
| This area was generated with Dilib version V0.6.33. |  |